Bausch + Lomb (BLCO) Expected to Announce Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is projected to announce its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect Bausch + Lomb to post earnings of $0.35 per share and revenue of $1.3834 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:00 AM ET.

Bausch + Lomb Stock Up 1.9%

Shares of NYSE BLCO opened at $17.04 on Monday. The company has a market cap of $6.04 billion, a price-to-earnings ratio of -19.59, a PEG ratio of 0.99 and a beta of 0.61. The company has a current ratio of 1.51, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76. Bausch + Lomb has a 12 month low of $10.45 and a 12 month high of $17.86. The stock has a 50-day moving average price of $16.99 and a two-hundred day moving average price of $15.74.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds and other institutional investors have recently made changes to their positions in BLCO. Northwestern Mutual Wealth Management Co. raised its holdings in Bausch + Lomb by 729.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after purchasing an additional 2,042 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Bausch + Lomb by 104.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after buying an additional 1,136 shares during the period. Wells Fargo & Company MN raised its stake in Bausch + Lomb by 31.2% during the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after buying an additional 1,403 shares during the last quarter. Focus Partners Wealth acquired a new position in Bausch + Lomb in the third quarter valued at $170,000. Finally, JPMorgan Chase & Co. acquired a new position in Bausch + Lomb in the second quarter valued at $200,000. 11.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently issued reports on BLCO. JPMorgan Chase & Co. upped their price objective on shares of Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bausch + Lomb in a research note on Wednesday, January 21st. Citigroup raised Bausch + Lomb from a “neutral” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Thursday, December 11th. Royal Bank Of Canada increased their target price on Bausch + Lomb from $19.00 to $21.00 and gave the company an “outperform” rating in a research report on Tuesday, January 27th. Finally, Wells Fargo & Company lifted their price target on Bausch + Lomb from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Friday, November 14th. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $17.42.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.